Publications by authors named "L Cove-Smith"
Background: The currently approved frontline treatments for diffuse pleural mesothelioma (DPM) are ipilimumab-nivolumab or platinum-pemetrexed. The addition of bevacizumab to chemotherapy improves overall survival (OS). While single-agent immunotherapy or chemotherapy-immunotherapy combinations are superior to chemotherapy monotherapy, there is a potential for synergistic triple combination of chemotherapy, bevacizumab, and immunotherapy.
View Article and Find Full Text PDFArticle Synopsis
- Second-line treatment for small-cell lung cancer (SCLC) typically depends on how long it's been since the last platinum therapy, with carboplatin and etoposide showing better results if the interval is over 90 days, but this study looks at its effectiveness post-chemo-immunotherapy.
- A retrospective review of 93 patients who received this rechallenge after initial chemo-immunotherapy revealed a 59.1% overall response rate, with a median progression-free survival of 5 months and overall survival of 7 months.
- The findings indicate that carboplatin and etoposide remain a valid second-line option for extensive-stage SCLC, providing consistent outcomes regardless of the platinum-free interval as long as it exceeds
Background: Extended pleurectomy decortication for complete macroscopic resection for pleural mesothelioma has never been evaluated in a randomised trial. The aim of this study was to compare outcomes after extended pleurectomy decortication plus chemotherapy versus chemotherapy alone.
Methods: MARS 2 was a phase 3, national, multicentre, open-label, parallel two-group, pragmatic, superiority randomised controlled trial conducted in the UK.
Article Synopsis
- The Christie NHS Foundation Trust launched an electronic patient-reported outcome measures (ePROMs) service for lung cancer patients in January 2019, enabling them to report symptoms and quality of life (QoL) online.
- Over 1,400 patients participated, with results showing significant differences in symptoms related to ECOG performance status and comorbidity scores, but no notable differences among age groups.
- Patients receiving palliative treatment reported improvements in cough and hemoptysis, though mobility declined; those undergoing radical thoracic radiotherapy experienced better hemoptysis but worse pain and fatigue.
Introduction: On the basis of the findings of the phase 3 PACIFIC trial (NCT02125461), durvalumab is standard of care for patients with stage III, unresectable NSCLC and no disease progression after concurrent chemoradiotherapy (cCRT). Many patients are considered unsuitable for cCRT owing to concerns with tolerability. The phase 2 PACIFIC-6 trial (NCT03693300) evaluates the safety and tolerability of durvalumab after sequential CRT (sCRT).
View Article and Find Full Text PDF